File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Glucocorticoid induced bone disorders in children: Research progress in treatment mechanisms

TitleGlucocorticoid induced bone disorders in children: Research progress in treatment mechanisms
Authors
Keywordsbone growth suppression
chondrocyte 3
glucocorticoid (GC)
growth hormone
growth plate
Issue Date2023
Citation
Frontiers in Endocrinology, 2023, v. 14, article no. 1119427 How to Cite?
AbstractLong-term or supra-physiological dose of glucocorticoid (GC) application in clinic can lead to impaired bone growth and osteoporosis. The side effects of GC on the skeletal system are particularly serious in growing children, potentially causing growth retardation or even osteoporotic fractures. Children’s bone growth is dependent on endochondral ossification of growth plate chondrocytes, and excessive GC can hinder the development of growth plate and longitudinal bone growth. Despite the availability of drugs for treating osteoporosis, they have failed to effectively prevent or treat longitudinal bone growth and development disorders caused by GCs. As of now, there is no specific drug to mitigate these severe side effects. Traditional Chinese Medicine shows potential as an alternative to the current treatments by eliminating the side effects of GC. In summary, this article comprehensively reviews the research frontiers concerning growth and development disorders resulting from supra-physiological levels of GC and discusses the future research and treatment directions for optimizing steroid therapy. This article may also provide theoretical and experimental insight into the research and development of novel drugs to prevent GC-related side effects.
Persistent Identifierhttp://hdl.handle.net/10722/363762

 

DC FieldValueLanguage
dc.contributor.authorHua, Junying-
dc.contributor.authorHuang, Jianping-
dc.contributor.authorLi, Gang-
dc.contributor.authorLin, Sien-
dc.contributor.authorCui, Liao-
dc.date.accessioned2025-10-10T07:49:10Z-
dc.date.available2025-10-10T07:49:10Z-
dc.date.issued2023-
dc.identifier.citationFrontiers in Endocrinology, 2023, v. 14, article no. 1119427-
dc.identifier.urihttp://hdl.handle.net/10722/363762-
dc.description.abstractLong-term or supra-physiological dose of glucocorticoid (GC) application in clinic can lead to impaired bone growth and osteoporosis. The side effects of GC on the skeletal system are particularly serious in growing children, potentially causing growth retardation or even osteoporotic fractures. Children’s bone growth is dependent on endochondral ossification of growth plate chondrocytes, and excessive GC can hinder the development of growth plate and longitudinal bone growth. Despite the availability of drugs for treating osteoporosis, they have failed to effectively prevent or treat longitudinal bone growth and development disorders caused by GCs. As of now, there is no specific drug to mitigate these severe side effects. Traditional Chinese Medicine shows potential as an alternative to the current treatments by eliminating the side effects of GC. In summary, this article comprehensively reviews the research frontiers concerning growth and development disorders resulting from supra-physiological levels of GC and discusses the future research and treatment directions for optimizing steroid therapy. This article may also provide theoretical and experimental insight into the research and development of novel drugs to prevent GC-related side effects.-
dc.languageeng-
dc.relation.ispartofFrontiers in Endocrinology-
dc.subjectbone growth suppression-
dc.subjectchondrocyte 3-
dc.subjectglucocorticoid (GC)-
dc.subjectgrowth hormone-
dc.subjectgrowth plate-
dc.titleGlucocorticoid induced bone disorders in children: Research progress in treatment mechanisms-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.3389/fendo.2023.1119427-
dc.identifier.scopuseid_2-s2.0-85153509523-
dc.identifier.volume14-
dc.identifier.spagearticle no. 1119427-
dc.identifier.epagearticle no. 1119427-
dc.identifier.eissn1664-2392-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats